137 related articles for article (PubMed ID: 21269600)
1. Selective glucocorticoid receptor (type II) antagonists prevent weight gain caused by olanzapine in rats.
Belanoff JK; Blasey CM; Clark RD; Roe RL
Eur J Pharmacol; 2011 Mar; 655(1-3):117-20. PubMed ID: 21269600
[TBL] [Abstract][Full Text] [Related]
2. Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain.
Belanoff JK; Blasey CM; Clark RD; Roe RL
Diabetes Obes Metab; 2010 Jun; 12(6):545-7. PubMed ID: 20518810
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats.
Beebe KL; Block T; Debattista C; Blasey C; Belanoff JK
Behav Brain Res; 2006 Aug; 171(2):225-9. PubMed ID: 16782211
[TBL] [Abstract][Full Text] [Related]
4. Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model.
Deng C; Lian J; Pai N; Huang XF
J Psychopharmacol; 2012 Sep; 26(9):1271-9. PubMed ID: 22695490
[TBL] [Abstract][Full Text] [Related]
5. LLY-2707, a novel nonsteroidal glucocorticoid antagonist that reduces atypical antipsychotic-associated weight gain in rats.
Sindelar DK; Carson MW; Morin M; Shaw J; Barr RJ; Need A; Alexander-Chacko J; Coghlan M; Gehlert DR
J Pharmacol Exp Ther; 2014 Jan; 348(1):192-201. PubMed ID: 24163440
[TBL] [Abstract][Full Text] [Related]
6. Mifepristone treatment of olanzapine-induced weight gain in healthy men.
Gross C; Blasey CM; Roe RL; Allen K; Block TS; Belanoff JK
Adv Ther; 2009 Oct; 26(10):959-69. PubMed ID: 19888560
[TBL] [Abstract][Full Text] [Related]
7. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression.
Han M; Deng C; Burne TH; Newell KA; Huang XF
Psychoneuroendocrinology; 2008 Jun; 33(5):569-80. PubMed ID: 18358632
[TBL] [Abstract][Full Text] [Related]
8. Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone.
Shobo M; Yamada H; Mihara T; Kondo Y; Irie M; Harada K; Ni K; Matsuoka N; Kayama Y
Behav Brain Res; 2011 Jan; 216(2):561-8. PubMed ID: 20816897
[TBL] [Abstract][Full Text] [Related]
9. Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways.
Lian J; Huang XF; Pai N; Deng C
Psychoneuroendocrinology; 2014 Oct; 48():77-86. PubMed ID: 24992721
[TBL] [Abstract][Full Text] [Related]
10. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.
Lykkegaard K; Larsen PJ; Vrang N; Bock C; Bock T; Knudsen LB
Schizophr Res; 2008 Aug; 103(1-3):94-103. PubMed ID: 18579346
[TBL] [Abstract][Full Text] [Related]
11. Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain.
Patil BM; Kulkarni NM; Unger BS
Eur J Pharmacol; 2006 Dec; 551(1-3):112-5. PubMed ID: 17046744
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of olanzapine-induced weight gain by the retinoid analog AM-80.
Richards M; Chiba S; Ninomiya M; Wakabayasi C; Kunugi H
Pharmacopsychiatry; 2013 Nov; 46(7):267-73. PubMed ID: 24105080
[TBL] [Abstract][Full Text] [Related]
13. Olanzapine-activated AMPK signaling in the dorsal vagal complex is attenuated by histamine H1 receptor agonist in female rats.
He M; Zhang Q; Deng C; Wang H; Huang XF
Endocrinology; 2014 Dec; 155(12):4895-904. PubMed ID: 25264935
[TBL] [Abstract][Full Text] [Related]
14. Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats.
Lazzari P; Serra V; Marcello S; Pira M; Mastinu A
Eur Neuropsychopharmacol; 2017 Jul; 27(7):667-678. PubMed ID: 28377074
[TBL] [Abstract][Full Text] [Related]
15. Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats.
Fell MJ; Marshall KM; Williams J; Neill JC
J Psychopharmacol; 2004 Jun; 18(2):149-55. PubMed ID: 15260902
[TBL] [Abstract][Full Text] [Related]
16. Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration.
Minet-Ringuet J; Even PC; Goubern M; Tomé D; de Beaurepaire R
Appetite; 2006 May; 46(3):254-62. PubMed ID: 16551485
[TBL] [Abstract][Full Text] [Related]
17. Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men.
Gross C; Blasey CM; Roe RL; Belanoff JK
Obesity (Silver Spring); 2010 Dec; 18(12):2295-300. PubMed ID: 20339369
[TBL] [Abstract][Full Text] [Related]
18. Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats.
Choi S; DiSilvio B; Unangst J; Fernstrom JD
Life Sci; 2007 Sep; 81(12):1024-30. PubMed ID: 17822717
[TBL] [Abstract][Full Text] [Related]
19. Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain.
Weston-Green K; Huang XF; Deng C
PLoS One; 2012; 7(3):e33548. PubMed ID: 22438946
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects.
Skrede S; Martins L; Berge RK; Steen VM; López M; Fernø J
Int J Neuropsychopharmacol; 2014 Jan; 17(1):91-104. PubMed ID: 23919889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
